An in vitro and in vivo investigation of the antimetastatic effects of a chinese medicinal decoction, erxian decoction, on human ovarian cancer models

Integrative Cancer Therapies

Volumn 12, Issue 4, 2013, Pages 336-346

  Chu, Ellie S M ^a   Sze, Stephen C W ^a   Cheung, Ho P ^a   Liu, Qing ^a   Ng, Tzi B ^b   Tong, Yao ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

antimetastasis; antitumor effect; Chinese medicinal decoction; Erxian Decoction; ovarian cancer

Indexed keywords

ANTIMETASTATIC AGENT; CHINESE DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERXIAN DECOCTION; GELATINASE A; GELATINASE B; MATRILYSIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER SIZE; CELL CYCLE PROGRESSION; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TUMOR XENOGRAFT; WESTERN BLOTTING; WOUND HEALING;

ANTIMETASTASIS; ANTITUMOR EFFECT; CHINESE MEDICINAL DECOCTION; ERXIAN DECOCTION; OVARIAN CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, NUDE; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PHYTOTHERAPY; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879391159     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735412464519     Document Type: Article

References (47)

1. Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV. Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen. Int J Cancer. 2010 ; 127: 2928-2935
2. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002 ; 288: 334-341
3. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Berchuck A. Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol. 2005 ; 193: 76-82
4. Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer. 2009 ; 115: 531-539
5. Qiu J. "Back to the future" for Chinese herbal medicines. Nat Rev Drug Discov. 2007 ; 6: 506-507
6. Li S, Han Q, Qiao C, Song J, Lung Cheng C, Xu H. Chemical markers for the quality control of herbal medicines: an overview. Chin Med. 2008 ; 3: 7
7. Li JJ, Li JT, Fu JP. Erxian tang - introduction of a Chinese herbal formula, clinical practice, and experimental studies. Chin J Integr Med. 2007 ; 13: 67-73
8. Wang CH, Zhang ZH, Ma J. Treatment of 50 cases of osteoporosis with Er-xian Decoction. Shan Xi Zhong Yi. 1998 ; 19: 205
9. Pharmacopoeia of the People's Republic of China. Beijing, China: Chemical Industry Press ; 2005 :
10. Wang Y, Dong H, Zhu M, et al. Icariin exerts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. Eur J Pharmacol. 2010 ; 635: 40-48
11. Cao W, Li XQ, Wang X, et al. A novel polysaccharide, isolated from Angelica sinensis (Oliv.) Diels induces the apoptosis of cervical cancer HeLa cells through an intrinsic apoptotic pathway. Phytomedicine. 2010 ; 17: 598-605
12. Sy LK, Yan SC, Lok CN, Man RY, Che CM. Timosaponin A-III induces autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells. Cancer Res. 2008 ; 68: 10229-10237
13. Bao W, Pan H, Lu M, Ni Y, Zhang R, Gong X. The apoptotic effect of sarsasapogenin from Anemarrhena asphodeloides on HepG2 human hepatoma cells. Cell Biol Int. 2007 ; 31: 887-892
14. Beral V, Million Women Study C. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003 ; 362: 419-427
15. Beral V, Million Women Study C, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007 ; 369: 1703-1710
16. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006 ; 113: 2425-2434
17. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007 ; 297: 1465-1477
18. Zhang L. The samples of effective clinical cases of Er Xian Tang application by professor Wenzhen Huang. Fujian J Tradit Chin Med. 2004 ; 53: 19-22
19. Dong BF, Fang ZQ, Shi JR. Effect of er xian decoction and its subdivisions on granulosa cells secretory function in rats [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 ; 26: 122-125
20. Nian H, Qin LP, Zhang QY, Zheng HC, Yu Y, Huang BK. Antiosteoporotic activity of Er-Xian Decoction, a traditional Chinese herbal formula, in ovariectomized rats. J Ethnopharmacol. 2006 ; 108: 96-102
21. Sze SC, Tong Y, Zhang YB, et al. A novel mechanism: Erxian Decoction, a Chinese medicine formula, for relieving menopausal syndrome. J Ethnopharmacol. 2009 ; 123: 27-33
22. Fortepiani LA, Zhang H, Racusen L, Roberts LJ, Reckelhoff JF. Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rats. Hypertension. 2003 ; 41: 640-645
23. Liu X, Lin Y, Situ H, Liu P, Zhou Q. Clinical study of chronological dosage regimen of modified Guilu Erxian decoction regulating bone marrow hematopoietic function of the breast cancer patients after chemotherapy. Liaoning J Tradit Chin Med. 2008 ; 35 ( 7 ):
24. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther. 2004 ; 10: 1032-1042
25. Sze SCW, Wong KL, Liu WK, et al. Regulation of p21, MMP-1 and MDR-1 expression in Human colon carcinoma HT29 by Tian Xian Liquid, a Chinese Medicine Formula, in vitro and in vivo. Integr Cancer Ther. 2011 ; 10: 58-69
26. Geback T, Schulz MM, Koumoutsakos P, Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques. 2009 ; 46: 265-274
27. Qin L, Han T, Zhang Q, et al. Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula. J Ethnopharmacol. 2008 ; 118: 271-279
28. Zhu Z, Xue LM, Han T, et al. Antiosteoporotic effects and proteomic characterization of the target and mechanism of an Er-Xian Decoction on osteoblastic UMR-106 and osteoclasts induced from RAW264.7. Molecules. 2010 ; 15: 4695-4710
29. Townson JL, Naumov GN, Chambers AF. The role of apoptosis in tumor progression and metastasis. Curr Mol Med. 2003 ; 3: 631-642
30. Zagouri F, Dimopoulos MA, Bournakis E, Papadimitriou CA. Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy. Eur J Gynaecol Oncol. 2010 ; 31: 268-277
31. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother. 2003 ; 52: 342-346
32. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000 ; 19: 3159-3167
33. Maihle NJ, Baron AT, Barrette BA, et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res. 2002 ; 107: 247-258
34. Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer. 1998 ; 78: 331-337
35. Cowden Dahl KD, Symowicz J, Ning Y, et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res. 2008 ; 68: 4606-4613
36. Cowden Dahl KD, Zeineldin R, Hudson LG. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res. 2007 ; 5: 413-421
37. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008 ; 1785: 232-265
38. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res. 2009 ; 15: 5297-5302
39. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009 ; 15: 220-231
40. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009 ; 15: 232-239
41. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993 ; 362: 841-844
42. Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003 ; 63: 5224-5229
43. Dean RA, Butler GS, Hamma-Kourbali Y, et al. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol. 2007 ; 27: 8454-8465
44. Dean RA, Overall CM. Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics. 2007 ; 6: 611-623
45. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004 ; 114: 623-633
46. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007 ; 67: 3310-3319
47. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005 ; 169: 681-691